Washington: A new medicated chewing gum has been developed for motion sickness, which could offer many advantages over conventional oral solid dosage forms.
About 33 percent of people are prone to motion sickness in mild conditions, and 66 percent are affected in more severe circumstances.
Lead researcher Mohsen Sadatrezaei of RoshaDarou Company and a team of researchers consisting of Niloufar Pouyan, Zoherh JafariAzar and Alireza Ghaffari from the Islamic Azad University School of Pharmaceutical Sciences (Tehran, Iran), have developed the prototype that will improve patient compliance and faster absorption through the cheek, which will alleviate motion sickness sooner.
A sensory panel was used to test faster absorption through the buccal cavity, which will result in earlier onset of action against motion sickness.
Panelists also ranked the gum on bitterness and easiness to chew.
“The main challenge in delivering drugs through chewing gum is masking the bitter taste of its active ingredient,” Sadatrezaei said.
“We have formulated dimenhydrinate as chewing gum with acceptable taste and sensory attributes.
“Dimenhydrinate is among the best drug candidates for treatment of motion sickness, providing a comfortable and acceptable drug delivery,” he added.